Health Care & Life Sciences » Biotechnology | Ligand Pharmaceuticals Inc.

Ligand Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
48,973.00
64,538.00
71,914.00
108,973.00
141,102.00
251,453
Cost of Goods Sold (COGS) incl. D&A
5,732.00
9,136.00
5,807.00
16,214.00
17,486.00
22,129
Gross Income
43,241.00
55,402.00
66,107.00
92,759.00
123,616.00
229,324
SG&A Expense
27,258.00
34,692.00
37,758.00
47,842.00
55,540.00
65,597
EBIT
15,983.00
20,710.00
28,349.00
44,917.00
68,076.00
163,727
Unusual Expense
4,637.00
6,219.00
21,392.00
4,066.00
620.00
5,400
Non Operating Income/Expense
63.00
1,671.00
2,533.00
2,419.00
1,983.00
11,707
Interest Expense
2,077.00
4,860.00
11,802.00
12,178.00
11,400.00
48,276
Pretax Income
9,206.00
11,302.00
35,329.00
7,960.00
57,231.00
173,330
Income Tax
374.00
410.00
192,115.00
10,327.00
44,675.00
30,009
Consolidated Net Income
8,832.00
10,892.00
227,444.00
2,367.00
12,556.00
143,321
Net Income
8,832.00
12,024.00
229,824.00
2,367.00
12,556.00
143,321
Net Income After Extraordinaries
6,244.00
12,024.00
229,824.00
3,098.00
12,556.00
143,321
Net Income Available to Common
8,832.00
12,024.00
229,824.00
2,367.00
12,556.00
143,321
EPS (Basic)
0.55
0.56
10.83
0.08
0.53
5.96
Basic Shares Outstanding
20,312.40
20,418.60
19,790.00
20,831.00
21,032.00
21,160
EPS (Diluted)
0.55
0.56
10.83
0.08
0.53
5.96
Diluted Shares Outstanding
20,745.50
21,433.20
21,227.90
20,831.00
23,481.00
24,067
EBITDA
18,646.00
23,367.00
30,976.00
56,207.00
80,596.00
180,419
Minority Interest Expense
-
1,132.00
2,380.00
-
-
-
Equity in Affiliates (Pretax)
-
-
5,143.00
23,132.00
2,048.00
50,187

About Ligand Pharmaceuticals

View Profile
Address
3911 Sorrento Valley Boulevard
San Diego California 92121
United States
Employees -
Website http://www.ligand.com
Updated 07/08/2019
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.